Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors

SAN FRANCISCO, Aug. 21 Medizone International,Inc. (Pink Sheets: MZEI) announces the appointment of Michael E. Shannon,M.A., M.Sc., M.D. to its Board of Directors. Dr. Shannon received his medicaldegree from Queen's University in Canada, which included advanced training insurgery and sports medicine. He also holds post-graduate degrees inneurochemistry and physiology. He has been actively engaged in appliedmedical research within these areas for over 27 years. He served in theCanadian Forces for 31 years retiring at the rank of Commodore (BrigadierGeneral equivalent) as Deputy Surgeon General for Canada. During the firstGulf War, Dr. Shannon served as the senior medical liaison officer for all ofthe Canadian forces. In 1996 he assumed responsibilities within Health Canadafor re-organizing the Canadian blood system. Working with both the provincialand federal governments, he oversaw the development of a new corporate entitydedicated exclusively to the management of blood services in Canada. He wasthen appointed Director General for the Laboratory Centre for Disease Control,a position he held for three years. In December 2000, Dr. Shannon left theCanadian federal government to pursue a new career in industry. In thatcapacity he simultaneously directed a phase III clinical trial in Canada, theUnited States and Great Britain for an artificial blood substitute product.Following completion of that work he was asked to accept a special assignmentwith the Canadian Federal Government Auditor General's office. His assignmentwas to conduct a cost benefit analysis of all government sponsored pharmacareprograms and make recommendations directly to the Parliament of Canada. Hisassignment and presentation to Parliament on that project was completed inNovember 2004. Dr. Shannon recently worked on a special project assignment asSenior Medical Advisor to the Canadian Public Health Agency. His assignmentwas to review and help rebuild the Canadian Public Health Agency's EmergencyMedical Response Capacity. His work in that regard with the Canadiangovernment was completed the end of July this year.

Internationally respected for his expertise, Dr. Shannon has been activelyengaged in medical bio-oxidative (O3 based), research since 1987 and wasdirectly responsible for the first human clinical trial to have ever beenapproved in North America which examined the efficacy of O3 delivered viaautohemotherapy in the treatment of AIDS. He was also responsible for severalprimate studies utilizing O3 involving scientists from various departmentswithin the Canadian Federal Government, as well as senior investigators fromMedizone International and Cornell University.

Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of themembers of the board and all of the Company's shareholders, we welcome Dr.Shannon to our Board of Directors. The wisdom and expertise Dr. Shannonbrings to Medizone is unparalleled in the history of our company. I considerhim a remarkable man and feel honored to be able to refer to him as aprofessional associate. This appointment signals an immense step forward inthe reorganization of Medizone International.

Medizone International, Inc., is a research and development stage companyengaged in the development of patented and unpatented technologies andprotocols for O3 based bio-oxidative treatment of diseases caused by lipidenveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS),Hepatitis B & C, and Herpes, the decontamination of blood, blood products andveterinarian serum products, and the treatment of external pathogenicconditions.

This Press Release contains certain forward looking statements thatinvolve substantial risks and uncertainties, including, but not limited to,the results of ongoing clinical studies, economic conditions, product andtechnology development, production efficiencies, product demand,

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...